Literature DB >> 22359410

Healing of intestinal inflammation by IL-22.

Atsushi Mizoguchi1.   

Abstract

An interleukin (IL)-10 family cytokine, IL-22 is characterized by several unique biological properties, including 1) the target restricted to innate cells; 2) the distinct expression pattern between large and small intestines; 3) alteration of the cellular source depending on several factors; 4) the dual abilities to serve as protective versus proinflammatory mediators in inflammatory responses; and 5) the close association with some major inflammatory bowel disease (IBD) susceptibility genes. The major functions of IL-22 in the intestine are the stimulation of epithelial cells to produce a wide variety of antibacterial proteins, the reinforcement of mucus barrier through stimulation of mucin 1 production under intestinal inflammatory conditions, and the enhancement of epithelial regeneration with goblet cell restitution. Through these beneficial functions, IL-22 contributes to the improvement of some types of experimental chronic colitis, which are mediated by T helper (Th)1 or Th2 responses. Most important, studies using both loss-of-function and gain-of-function approaches have clearly demonstrated the ability of IL-22 to promote intestinal wound healing from acute intestinal injury. These findings highlight IL-22 as an attractive and promising target for future IBD therapy. Alternatively, the enormous progress in the field of IL-22 biology has also suggested more complicated mechanisms with the IL-22 pathway than previously predicted. This review article briefly summarizes previous and current knowledge on IL-22 particularly associated with intestinal inflammation.
Copyright © 2012 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22359410      PMCID: PMC3366176          DOI: 10.1002/ibd.22929

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  95 in total

1.  Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract.

Authors:  Ivan Monteleone; Angelamaria Rizzo; Massimiliano Sarra; Giuseppe Sica; Pierpaolo Sileri; Livia Biancone; Thomas T MacDonald; Francesco Pallone; Giovanni Monteleone
Journal:  Gastroenterology       Date:  2011-04-16       Impact factor: 22.682

2.  A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist.

Authors:  W Xu; S R Presnell; J Parrish-Novak; W Kindsvogel; S Jaspers; Z Chen; S R Dillon; Z Gao; T Gilbert; K Madden; S Schlutsmeyer; L Yao; T E Whitmore; Y Chandrasekher; F J Grant; M Maurer; L Jelinek; H Storey; T Brender; A Hammond; S Topouzis; C H Clegg; D C Foster
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

3.  Hydrodynamic-based delivery of an interleukin-22-Ig fusion gene ameliorates experimental autoimmune myocarditis in rats.

Authors:  He Chang; Haruo Hanawa; Hui Liu; Tsuyoshi Yoshida; Manabu Hayashi; Ritsuo Watanabe; Satoru Abe; Ken Toba; Kaori Yoshida; Raafat Elnaggar; Shiro Minagawa; Yuji Okura; Kiminori Kato; Makoto Kodama; Hiroki Maruyama; Junichi Miyazaki; Yoshifusa Aizawa
Journal:  J Immunol       Date:  2006-09-15       Impact factor: 5.422

4.  Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa.

Authors:  Kerstin Wolk; Katarzyna Warszawska; Conny Hoeflich; Ellen Witte; Sylke Schneider-Burrus; Katrin Witte; Stefanie Kunz; Annette Buss; Hans Joachim Roewert; Markus Krause; Ansgar Lukowsky; Hans-Dieter Volk; Wolfram Sterry; Robert Sabat
Journal:  J Immunol       Date:  2010-12-08       Impact factor: 5.422

Review 5.  Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22.

Authors:  Gregory F Sonnenberg; Lynette A Fouser; David Artis
Journal:  Nat Immunol       Date:  2011-05       Impact factor: 25.606

Review 6.  Recent advances in IL-22 biology.

Authors:  Lauren A Zenewicz; Richard A Flavell
Journal:  Int Immunol       Date:  2011-03       Impact factor: 4.823

7.  Imbalance of NKp44(+)NKp46(-) and NKp44(-)NKp46(+) natural killer cells in the intestinal mucosa of patients with Crohn's disease.

Authors:  Tetsuro Takayama; Nobuhiko Kamada; Hiroshi Chinen; Susumu Okamoto; Mina T Kitazume; Jonathan Chang; Yumi Matuzaki; Sadafumi Suzuki; Akira Sugita; Kazutaka Koganei; Tadakazu Hisamatsu; Takanori Kanai; Toshifumi Hibi
Journal:  Gastroenterology       Date:  2010-06-01       Impact factor: 22.682

8.  Interleukin-22 deficiency accelerates the rejection of full major histocompatibility complex-disparate heart allografts.

Authors:  P Kapessidou; L Poulin; L Dumoutier; M Goldman; J-C Renauld; M Y Braun
Journal:  Transplant Proc       Date:  2008-06       Impact factor: 1.066

9.  Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease.

Authors:  Lauren A Zenewicz; George D Yancopoulos; David M Valenzuela; Andrew J Murphy; Sean Stevens; Richard A Flavell
Journal:  Immunity       Date:  2008-12-19       Impact factor: 31.745

10.  Increased susceptibility to colitis and colorectal tumors in mice lacking core 3-derived O-glycans.

Authors:  Guangyu An; Bo Wei; Baoyun Xia; J Michael McDaniel; Tongzhong Ju; Richard D Cummings; Jonathan Braun; Lijun Xia
Journal:  J Exp Med       Date:  2007-05-21       Impact factor: 14.307

View more
  58 in total

1.  The necroptosis adaptor RIPK3 promotes injury-induced cytokine expression and tissue repair.

Authors:  Kenta Moriwaki; Sakthi Balaji; Thomas McQuade; Nidhi Malhotra; Joonsoo Kang; Francis Ka-Ming Chan
Journal:  Immunity       Date:  2014-10-16       Impact factor: 31.745

2.  Neutrophils enlist IL-22 to restore order in the gut.

Authors:  Timothy L Denning; Charles A Parkos
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-19       Impact factor: 11.205

Review 3.  New targets for mucosal healing and therapy in inflammatory bowel diseases.

Authors:  M F Neurath
Journal:  Mucosal Immunol       Date:  2013-10-02       Impact factor: 7.313

Review 4.  Resolution of Crohn's disease.

Authors:  Heike Schmitt; Clemens Neufert; Markus F Neurath; Raja Atreya
Journal:  Semin Immunopathol       Date:  2019-09-24       Impact factor: 9.623

Review 5.  A breakthrough in probiotics: Clostridium butyricum regulates gut homeostasis and anti-inflammatory response in inflammatory bowel disease.

Authors:  Takanori Kanai; Yohei Mikami; Atsushi Hayashi
Journal:  J Gastroenterol       Date:  2015-05-05       Impact factor: 7.527

Review 6.  Role of interleukin-22 in inflammatory bowel disease.

Authors:  Lin-Jing Li; Chen Gong; Mei-Hua Zhao; Bai-Sui Feng
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

Review 7.  Leukocyte-epithelial interactions and mucosal homeostasis.

Authors:  Jason D Matthews; Caroline M Weight; Charles A Parkos
Journal:  Toxicol Pathol       Date:  2013-11-27       Impact factor: 1.902

Review 8.  Pathogenesis of NEC: Role of the innate and adaptive immune response.

Authors:  Timothy L Denning; Amina M Bhatia; Andrea F Kane; Ravi M Patel; Patricia W Denning
Journal:  Semin Perinatol       Date:  2016-12-09       Impact factor: 3.300

Review 9.  Could a swimming creature inform us on intestinal diseases? Lessons from zebrafish.

Authors:  Ye Yang; Sarah Tomkovich; Christian Jobin
Journal:  Inflamm Bowel Dis       Date:  2014-05       Impact factor: 5.325

Review 10.  Where are we on worms?

Authors:  David E Elliott; Joel V Weinstock
Journal:  Curr Opin Gastroenterol       Date:  2012-11       Impact factor: 3.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.